

Breast Cancer

The effect of a new medicine (giredestrant or GDC-9545) in patients with ER+ positive breast cancer

A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Trial Status
Completed

Trial Runs In
6 Countries

Trial Identifier
NCT03916744 2018-003798-85
GO40987

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT03916744 2018-003798-85 GO40987
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
≥18 Years

Healthy Volunteers
No

This clinical trial was done to study a new medicine called, “giredestrant”, also known as “GDC-9545”, for the treatment of patients with “ER+ positive breast cancer”. This study was done to find out whether giredestrant was effective in slowing down ER+ breast cancer cell growth in patients. Researchers also wanted to find out if it was safe and if patients could tolerate this medicine. Seventy-five patients with HER+ breast cancer signed up for the study at 15 study centers across five countries.